Second-line drug therapy for patients with Type 2 Diabetes

A Consensus Statement from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group

November 19, 2018

The Kaiser Permanente ICVH group is aware of the new treatment recommendations published in the American Diabetes Association’s (ADA) Management of Hyperglycemia in Type 2 Diabetes 2018 Consensus Report. The ADA places newer diabetic medications such as SGLT 2 inhibitors and GLP 1 agonists after initial treatment with metformin and earlier in their treatment algorithm, most specifically for patients with established Coronary Artery Disease (CAD), Chronic Heart Failure (CHF), and Chronic Kidney Disease (CKD). We are currently actively evaluating how these new medications should be used for hyperglycemic treatment within our KP National Diabetes guideline. Our guideline recommendations regarding the progression of oral/injectable medications (including insulin) are evidence-based, of established efficacy, and are clinically appropriate in our patients with type 2 diabetes. We have commissioned an independent group to do a high-quality systematic review of these newer diabetic medications with results forthcoming within the next month.

The National KP Diabetes recommendations will be formally updated following this comprehensive review of the literature and inter-regional vetting with clinical leads and National Guideline Directors (NGD). As we evaluate the results, we will ensure the proper placement of these medications in our treatment algorithm for all our patients with type 2 diabetes, including those with co-morbidities such as CAD, CHF, and CKD.

John Martin, MD, FACP, AAHIVS
KP National Diabetes Lead
KP Southern California Diabetes Co-Lead

David McCulloch, MD
KP National Guideline Director
KP Washington Medical Director for Clinical Improvement

Alistair Bahar, MD
KP National Diabetes GDT Member
KP Northwest

Jennifer Loh, MD
KP National Diabetes GDT Member
KP Hawaii

Anna Cosyleon, MD
KP National CAD GDT Member
KP Colorado Diabetes and Blood Pressure Lead

Lisa Gilliam, MD, PhD
KP National Diabetes GDT Member
KP Northern California

Belkis Pimentel
KP National Guideline Director
KP Georgia Program Director, Quality Performance and Population Health

Ronald Scott, MD
KP National ICVH and Cholesterol Clinical Lead
KP Southern California CVD Co-Lead

Beth Liles, MD, MCR
KP National ICVH Methodologist
KP Northwest

Sandra Koyama, MD
KP National Heart Failure Lead
KP Southern California Heart Failure Lead

Reference: